Two independent studies reported progress on genomic assays that predict sentinel lymph node metastasis in melanoma and could reduce the need for diagnostic nodal surgery. Mayo Clinic and SkylineDx published a JAMA Surgery paper on a genomic test designed to forecast lymph node involvement and guide biopsy decisions; a multicenter Moffitt-led trial validated a gene expression profile test to identify low‑risk patients. Both tests integrate molecular profiling with clinicopathologic features to stratify metastasis risk. The Moffitt multicenter study and Mayo/SkylineDx data showed the assays can identify patients with low probability of nodal disease, potentially sparing them sentinel node biopsy and its morbidity. Investigators noted prospective clinical implementation will require regulatory review, payer engagement, and demonstration of how test‑guided management affects outcomes and resource use.